| Market Capitalization (Millions $) |
5,809 |
| Shares
Outstanding (Millions) |
123 |
| Employees |
1,779 |
| Revenues (TTM) (Millions $) |
692 |
| Net Income (TTM) (Millions $) |
-512 |
| Cash Flow (TTM) (Millions $) |
231 |
| Capital Exp. (TTM) (Millions $) |
20 |
Guardant Health Inc
Guardant Health Inc. is a leading precision oncology company that aims to transform cancer care through comprehensive genomic sequencing solutions. The company is based in Redwood City, California, and was founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz.
Guardant Health's core technology is called Guardant360, a non-invasive liquid biopsy test that uses genomic sequencing to analyze a patient's cancer. This test allows oncologists to identify mutations and alterations in a patient's cancer DNA, which can help guide treatment decisions. In addition, Guardant Health has developed a range of other liquid biopsy tests, including GuardantOMNI, GuardantINFORM, and GuardantHEALTHY, which can detect cancer early, monitor disease progression, and identify potential relapse.
Guardant Health has also developed proprietary bioinformatics algorithms and machine learning techniques to interpret the large amounts of genomic data generated by these tests. These algorithms are used to predict a patient's response to various treatment options and identify new targets for therapeutics.
Guardant Health has partnerships with several global pharmaceutical companies to develop companion diagnostic tests for their cancer therapies. In addition, the company has formed collaborations with leading cancer centers and research institutions to conduct clinical trials and advance the use of liquid biopsies in cancer care.
In 2018, Guardant Health went public on the NASDAQ stock exchange, and its shares are now listed under the symbol GH. The company has rapidly grown its revenue and customer base, and in 2020, it was named one of the fastest-growing companies in North America by Deloitte's Technology Fast 500.
Guardant Health's mission is to help improve outcomes for cancer patients through precision oncology. The company is dedicated to using the power of genomics and data science to revolutionize cancer care and ultimately, find a cure for this devastating disease.
Company Address: 3100 Hanover Street Palo Alto 94304 CA
Company Phone Number: 698-8887 Stock Exchange / Ticker: NASDAQ GH
|
